# EDGAR Filing Document

**Accession Number:** 0002044725
**File Stem:** 0001193125-26-093978
**Filing Date:** 2026-3
**Character Count:** 28135
**Document Hash:** 980a5ff4f9b6fd3349ed05be2782110e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-093978.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0001193125-26-093978

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 18

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260305

**EFFECTIVENESS DATE**: 20260305

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evommune, Inc.
- **CENTRAL INDEX KEY:** 0002044725
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 850742575
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294045
- **FILM NUMBER:** 26726292

**BUSINESS ADDRESS:**
- **STREET 1:** 1841 PAGE MILL RD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
- **BUSINESS PHONE:** (650) 223-7745

**MAIL ADDRESS:**
- **STREET 1:** 1841 PAGE MILL RD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304

**As filed with the Securities and Exchange Commission on March 5, 2026** 

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

------

**FORM S-8**

**REGISTRATION STATEMENT** 

***UNDER*** 

***THE SECURITIES ACT OF 1933*** 

------

**Evommune, Inc.** 

**(Exact name of registrant as specified in its charter)**

------

---

| | |
|:---|:---|
| **Delaware** | **85-0742575** |
| (State or Other Jurisdiction<br>of Incorporation) | (IRS Employer<br>Identification No.) |
| **1841 Page Mill Road, Suite 100**<br>**Palo Alto, CA** | **94304** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**Evommune, Inc. 2025 Equity Incentive Plan** 

**(Full titles of the plans)** 

**Luis Peña** 

**Chief Executive Officer** 

**Evommune, Inc. 1841 Page Mill Road, Suite 100** 

**Palo Alto, CA 94304** 

**Tel: (925) 247-4481** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

------

***Copies to:*** 

**Eric Blanchard** 

**Minkyu Park** 

**Cooley LLP** 

**500 Boylston Street, 14th Floor** 

**Boston, MA 02116** 

**Tel: (617) 937-2300** 

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large Accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**Explanatory Note**

Evommune, Inc. (the "***Registrant***") is filing this Registration Statement on Form S-8 for the purpose of registering 1,576,204 shares of the Registrant's common stock, par value $0.0001 (the "***Common Stock***"), issuable to eligible persons under the Registrant's 2025 Equity Incentive Plan (the "***2025 Plan***"), which Common Stock is in addition to the shares of Common Stock registered on the Registrant's [<u>Form S-8</u>](https://www.sec.gov/Archives/edgar/data/2044725/000119312525272519/d78726ds8.htm) filed with the Commission on November 7, 2025 (File No. 333-291386) (the "***Prior Registration Statement***"). The additional shares of Common Stock under the 2025 Plan have become reserved for issuance as a result of the operation of the "evergreen" provisions in the 2025 Plan, which provide that the total number of shares subject to such plan will be increased on the first day of each calendar year pursuant to a specified formula.

This Registration Statement relates to securities of the same class as that to which the Prior Registration Statement relate and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statement, to the extent relating to the registration of Common Stock issuable under the 2025 Plan, are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

**PART I** 

**INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS** 

The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act of 1933, as amended (the "Securities Act") and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and Exchange Commission (the "Commission") and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act.

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

---

| | |
|:---|:---|
| **Item 3.** | **Incorporation of Documents by Reference.**  |

---

The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the Commission:

&nbsp;&nbsp;&nbsp;&nbsp;(a) the Registrant's Annual Report on [<u>Form 10-K</u>](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/evmn-20251231.htm) for the fiscal year ended December 31, 2025 filed with the Commission on March 5, 2026;

&nbsp;&nbsp;&nbsp;&nbsp;(b) the Registrant's Current Report on [<u>Form 8-K</u>](https://www.sec.gov/Archives/edgar/data/2044725/000119312526049888/evmn-20260212.htm) filed with the SEC on February 13, 2026; and

&nbsp;&nbsp;&nbsp;&nbsp;(c) The description of the Registrant's Common Stock contained in the Registrant's Registration Statement on [<u>Form 8-A</u>](https://www.sec.gov/Archives/edgar/data/2044725/000119312525264660/d80636d8a12b.htm) filed on November 4, 2025 (File No. 001-42938) under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including any amendment or report filed for the purpose of updating such description, including [<u>Exhibit 4.3</u>](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/evmn-ex4_3.htm) to the Registrant's Annual Report on Form 10-K filed with the SEC on March 5, 2026.

All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or portions thereof that are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

---

| | |
|:---|:---|
| **Item 4.** | **Description of Securities.**  |

---

Not applicable.

------

---

| | |
|:---|:---|
| **Item 5.** | **Interests of Named Experts and Counsel.**  |

---

Not applicable.

---

| | |
|:---|:---|
| **Item 6.** | **Indemnification of Directors and Officers.**  |

---

Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation's board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act. The Registrant's amended and restated certificate of incorporation permits indemnification of its directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law, and the Registrant's amended and restated bylaws provide that the Registrant will indemnify its directors and executive officers and permit it to indemnify its other officers, employees, and other agents, in each case to the maximum extent permitted by the Delaware General Corporation Law.

The Registrant has entered into indemnification agreements with its directors and executive officers, whereby it has agreed to indemnify its directors and executive officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or executive officer was, or is threatened to be made, a party by reason of the fact that such director or executive officer is or was a director, executive officer, employee or agent of the Registrant, provided that such director or executive officer acted in good faith and in a manner that the director or executive officer reasonably believed to be in, or not opposed to, the best interest of the Registrant. At present, there is no pending litigation or proceeding involving a director or executive officer of the Registrant regarding which indemnification is sought, nor is the Registrant aware of any threatened litigation that may result in claims for indemnification.

The Registrant maintains insurance policies that indemnify its directors and officers against various liabilities arising under the Securities Act and the Exchange Act, that might be incurred by any director or officer in his capacity as such.

---

| | |
|:---|:---|
| **Item 7.** | **Exemption from Registration Claimed.**  |

---

Not applicable.

------

---

| | |
|:---|:---|
| **Item 8.** | **Exhibits.**  |

---

The exhibits to this Registration Statement are listed below:

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 4.1 | [<u>Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-42938), filed with the Commission on November 7, 2025).</u>](https://www.sec.gov/Archives/edgar/data/2044725/000119312525272282/d38367dex31.htm) |
| 4.2 | [<u>Amended and Restated Bylaws of the Registrant, as currently in effect (incorporated herein by reference to Exhibit 3.4 to the Registrant's Registration Statement on Form S-1 (File No. 333-290793), filed with the Commission on October 9, 2025).</u>](https://www.sec.gov/Archives/edgar/data/2044725/000119312525235673/d771358dex34.htm) |
| 4.3 | [<u>Form of Common Stock Certificate of the Registrant (incorporated herein by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-290793), filed with the Commission on October 9, 2025).</u>](https://www.sec.gov/Archives/edgar/data/2044725/000119312525235673/d771358dex41.htm) |
| 5.1\* | [<u>Opinion of Cooley LLP.</u>](evmn-ex5_1.htm) |
| 23.1\* | [<u>Consent of BDO USA, P.C., Independent Registered Public Accounting Firm.</u>](evmn-ex23_1.htm) |
| 23.2\* | [<u>Consent of Cooley LLP (included in Exhibit 5.1).</u>](evmn-ex5_1.htm) |
| 24.1\* | [<u>Power of Attorney (included on the signature page).</u>](#poa) |
| 99.1 | [<u>Evommune, Inc. 2025 Equity Incentive Plan (incorporated by reference to Exhibit 99.3 to the Registrant's Registration Statement on Form S-8 (File No. 333-291386), filed with the Commission on November 7, 2026).</u>](https://www.sec.gov/Archives/edgar/data/2044725/000119312525272519/d78726dex993.htm) |
| 99.2 | [<u>Forms of Stock Option Grant Notice, Option Agreement, Notice of Exercise, Restricted Stock Unit Agreement and Restricted Stock Unit Grant Notice under the 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.3(b) to the Registrant's Registration Statement on Form S-1/A (File No. 333-290793), filed with the Commission on October 17, 2025).</u>](https://www.sec.gov/Archives/edgar/data/2044725/000119312525242492/d771358dex103b.htm) |
| 107\* | [<u>Filing Fee Table.</u>](evmn_exfilingfees.htm) |

---

\* Filed herewith

------

---

| | |
|:---|:---|
| **Item 9.** | **Undertakings.**  |

---

(a) The undersigned Registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement; and

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.

*Provided, however,* that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Palo Alto, California, on March 5, 2026.

---

| | | |
|:---|:---|:---|
|  | Evommune, Inc. | Evommune, Inc. |
| Date: March 5, 2026 | By: | /s/ Luis Peña |
|  |  | Luis Peña |
|  |  | President and Chief Executive Officer |
|  |  | (Principal Executive Officer) |

---

**POWER OF ATTORNEY** 

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Luis Peña and Kyle Carver and each of them, as his or her true and lawful attorney-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| /s/ Luis Peña | President, Chief Executive Officer and Director | March 5, 2026 |
| Luis Peña | (Principal Executive Officer) |  |
| /s/ Kyle Carver | Chief Financial Officer | March 5, 2026  |
| Kyle Carver, CPA, MBA | (Principal Financial and Accounting Officer) |  |
| /s/ Benjamin F. McGraw | Chairman | March 5, 2026 |
| Benjamin F. McGraw, III, Pharm.D. |  |  |
| /s/ Eugene A. Bauer | Director  | March 5, 2026 |
| Eugene A. Bauer, M.D. |  |  |
| /s/ David E. Cohen | Director  | March 5, 2026 |
| David E. Cohen, M.D., M.P.H. |  |  |
| /s/ Derek DiRocco | Director  | March 5, 2026 |
| Derek DiRocco, Ph.D. |  |  |
| /s/ Arthur Kirsch | Director  | March 5, 2026 |
| Arthur Kirsch |  |  |
| /s/ Rob Hopfner | Director  | March 5, 2026 |
| Rob Hopfner, R.Ph., Ph.D. |  |  |
| /s/ Felice Verduyn-van Weegen | Director | March 5, 2026 |
| Felice Verduyn-van Weegen |  |  |

---

------

## Exhibit 5.1

![img131276556_0.jpg](img131276556_0.jpg)![gfx131276556_0.gif](gfx131276556_0.gif)

Cooley LLP 500 Boylston Street, 14<sup>th</sup> Floor, Boston, MA 02116-3736<br>t: +1 (617) 937-2300 f: +1 (617) 937-2400 cooley.com

Eric Blanchard+1 (617) 937-2445eblanchard@cooley.com Exhibit 5.1 <br>

March 5, 2026

Evommune, Inc.

1841 Page Mill Road, Suite 100

Palo Alto, CA 94304

Ladies and Gentlemen:

We have acted as counsel to Evommune, Inc., a Delaware corporation (the "***Company***"), in connection with the filing of a Registration Statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***") covering the offering by the Company of up to 1,576,204 shares (the "***Shares***") of its common stock, par value $0.0001 per share ("***Common Stock***"), pursuant to the Company's 2025 Equity Incentive Plan (the "***Plan***").

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and the related prospectuses, (b) the Company's certificate of incorporation and bylaws, each as currently in effect, (c) the Plan and (d) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plan, the Registration Statement and the related prospectuses, will be validly issued, fully paid, and nonassessable (except as to shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

------

![img131276556_1.jpg](img131276556_1.jpg)![gfx131276556_0.gif](gfx131276556_0.gif)

Cooley LLP 500 Boylston Street, 14<sup>th</sup> Floor, Boston, MA 02116-3736<br>t: +1 (617) 937-2300 f: +1 (617) 937-2400 cooley.com

&nbsp;&nbsp;Evommune, Inc.<br>March 5, 2026<br>Page 2<br>

Sincerely,

Cooley LLP

By:<u>/s/ Eric Blanchard</u> 

Eric Blanchard

------

## Exhibit 23.1

**Exhibit 23.1**

**<u>Consent of Independent Registered Public Accounting Firm</u>**

We hereby consent to the incorporation by reference in this Registration Statement of our report dated March 5, 2026, relating to the consolidated financial statements of Evommune, Inc. (the Company)appearing in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

/s/ BDO USA, P.C.

New York, New York

March 5, 2026

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of** Filing Fee **Tables**  |
| S-8  |
| Evommune, Inc.  |

---

**Table 1: Newly Registered Securities** <br>

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Security Type <br>| **Security Class Title** <br>| **Fee Calculation Rule** <br>| **Amount Registered** <br>| **Proposed Maximum Offering Price Per Unit** <br>| **Maximum Aggregate Offering Price** <br>| **Fee Rate** <br>| **Amount of Registration Fee** <br>|
| 1  | Equity  | Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the 2025 Equity Incentive Plan  | Other  | 1576204  | $23.18  | $36536409.00 | 0.0001381  | $5046.00 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $36536409.00<br>|  | $5046.00  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00 <br>|
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $5046.00  |

---

------

**Offering Note** <br>

---

| | |
|:---|:---|
| 1 <br>| (A) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of Common Stock ("Common Stock") of Evommune, Inc. (the "Registrant") that become issuable under the Registrant's 2025 Equity Incentive Plan (the "2025 Plan") by reason of any stock dividend, stock split, recapitalization or other similar transaction that results in an increase in the number of the Registrant's outstanding shares of Common Stock. (B) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and (h) of the Securities Act, and is based upon the price of $23.18 per share, the average of the high and low prices of Common Stock as reported on the New York Stock Exchange on March 4, 2026. (C) Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the 2025 Plan on January 1, 2026 pursuant to an "evergreen" provision contained in the 2025 Plan. Pursuant to such evergreen provision, on January 1st of each year commencing on January 1, 2026 and ending on (and including) January 1, 2035, the number of shares authorized for issuance under the 2025 Plan is automatically increased by a number equal to five percent (5.0%) of the total number of shares of Common Stock equal to the sum of (i) the number of shares of Common Stock issued and outstanding, (ii) the total number of shares of Common Stock subject to pre-funded warrants (if any), and (iii) the total number of shares of Common Stock issuable upon the conversion of preferred stock (if any), on December 31 of the preceding year; provided, however, that the Registrant's board of directors may act prior to January 1st of a given year to provide that the increase for such year will be a lesser number of shares of Common Stock.  |

---

------

---

| | |
|:---|:---|
| **Table 2: Fee Offset Claims and Sources**  | **☑Not Applicable**  |

---

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Registrant or Filer Name**  | **Form or Filing Type**  | **File Number**  | **Initial Filing Date**  | **Filing Date**  | **Fee Offset Claimed**  | **Security Type Associated with Fee Offset Claimed**  | **Security Title Associated with Fee Offset Claimed**  | **Unsold Securities Associated with Fee Offset Claimed**  | **Unsold Aggregate Offering Amount Associated with Fee Offset Claimed**  | **Fee Paid with Fee Offset Source**  |
| **Rule 457(p)**  | **Rule 457(p)**  | **Rule 457(p)**  | **Rule 457(p)**  | **Rule 457(p)**  | **Rule 457(p)**  | **Rule 457(p)**  | **Rule 457(p)**  | **Rule 457(p)**  | **Rule 457(p)**  | **Rule 457(p)**  | **Rule 457(p)**  |
| Fee Offset Claims  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  |
| Fee Offset Sources  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  | N/A  |

---

------